Cover Image

Bosentan and sildenafil in the treatment of HIV-associated pulmonary hypertension

Pierangelo Chinello, Stefania Cicalini, Andrea Cortese, Maria Paola Cicini, Nicola Petrosillo
  • Pierangelo Chinello
    Second Infectious Diseases Unit, L. Spallanzani National Institute for Infectious Diseases, Rome, Italy | pierangelo.chinello@inmi.it
  • Stefania Cicalini
    Second Infectious Diseases Unit, L. Spallanzani National Institute for Infectious Diseases, Rome, Italy
  • Andrea Cortese
    U.O. Diagnostica per Immagini, S. Camillo-Forlanini Hospital, Rome, Italy
  • Maria Paola Cicini
    III Cardiology Unit, S. Camillo-Forlanini Hospital, Rome, Italy
  • Nicola Petrosillo
    Second Infectious Diseases Unit, L. Spallanzani National Institute for Infectious Diseases, Rome, Italy

Abstract

We present the case of an HIV/HCV-coinfected patient with HIV-related pulmonary hypertension (HRPH) who experienced a good clinical and functional response to bosentan, with a subsequent switch to oral sildenafil due to increased transaminase levels. Bosentan resulted less handy in this case, probably due to both side effects and co-morbidities.

Keywords

bosentan; sildenafil; HIV; pulmonary arterial hypertension

Full Text:

PDF
HTML
Submitted: 2011-08-11 17:47:31
Published: 2011-11-22 14:19:00
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
1179

Views:
PDF
185
HTML
48

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2011 Pierangelo Chinello, Stefania Cicalini, Andrea Cortese, Maria Paola Cicini, Nicola Petrosillo

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2016     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185